Cargando…
Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects
BACKGROUND: Lixisenatide is a once‐daily, prandial, short‐acting glucagon‐like peptide‐1 receptor agonist. Its main antidiabetic effect is to delay gastric emptying to control postprandial plasma glucose excursions. The dose–response relationship of the integrated insulinotropic and gastrostatic res...
Autores principales: | Becker, Reinhard H. A., Stechl, Jens, Steinstraesser, Axel, Golor, Georg, Pellissier, Franck |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4744661/ https://www.ncbi.nlm.nih.gov/pubmed/25773712 http://dx.doi.org/10.1002/dmrr.2647 |
Ejemplares similares
-
Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes – a study in both people with type 2 diabetes and healthy subjects
por: Becker, R H A, et al.
Publicado: (2014) -
Glucose-dependent Insulinotropic Polypeptide (GIP) Resistance and β-cell Dysfunction Contribute to Hyperglycaemia in Acromegaly
por: Shekhawat, Vikram Singh, et al.
Publicado: (2019) -
Benefit of insulin glargine/lixisenatide for reducing residual hyperglycaemia in Japan: Post hoc analysis of the LixiLan JP‐O2 trial
por: Iizuka, Katsumi, et al.
Publicado: (2021) -
Administration of Jerusalem artichoke reduces the postprandial plasma glucose and glucose-dependent insulinotropic polypeptide (GIP) concentrations in humans
por: Takahashi, Hirokazu, et al.
Publicado: (2022) -
Association of Genetic Variants with Isolated Fasting Hyperglycaemia and Isolated Postprandial Hyperglycaemia in a Han Chinese Population
por: Kong, Xiaomu, et al.
Publicado: (2013)